SCHEMBL4651124

SCHEMBL4651124

N[C@@]1(CO)CCc2[nH]c3ccccc3c2C1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
NR2E1 Q9Y466 2/20 0.44
KDM4E B2RXH2 3/20 0.44
HTR5A P47898 1/20 0.44
NISCH Q9Y2I1 1/20 0.44
TAAR1 Q96RJ0 1/20 0.43
CHRNA7 P36544 1/20 0.41
ACHE P22303 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
BAZ2B Q9UIF8 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
TACR1 P25103 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4652083 1.00 HTR2A (0.45) HTR2AHTR2CNR2E1KDM4EHTR5A
SCHEMBL4652170 0.81 BAZ2B (0.44) ACHEALDH1A1MAPTBAZ2B
SCHEMBL14029096 0.80 HTR2A (0.45) HTR2AHTR2CNR2E1KDM4EHTR5A
SCHEMBL4652074 0.79 TAAR1 (0.48) KDM4ENISCHTAAR1ALDH1A1LMNA
SCHEMBL4652024 0.79 MAPK10 (0.36) NISCHTAAR1MAPT
SCHEMBL4653210 0.78 CFTR (0.41) TACR1
SCHEMBL29025621 0.78 HTR2A (0.43) HTR2AHTR2CNR2E1KDM4EHTR5A
SCHEMBL6529663 0.78 HTR2A (0.49) HTR2AHTR2CNR2E1KDM4EHTR5A
SCHEMBL4651181 0.77 BAZ2B (0.51) LMNAMAPTBAZ2B
SCHEMBL6526481 0.76 LMNA (0.45) HTR2AHTR2CNR2E1KDM4EHTR5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275083-A1 2,3,4,9-TETRAHYDRO-1H-CARBAZOLES BAYER SCHERING PHARMA AG (DE) 2008-11-06 US claimed
WO-2008116671-A1 2,3,4,9-TETRAHYDRO-1H-CARBAZOLES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-10-02 WO claimed
EP-1975159-A1 2,3,4,9-Tetrahydro-1H-carbazoles Bayer Schering Pharma Aktiengesellschaft (DE) 2008-10-01 EP claimed
US-20080275083-A1 2,3,4,9-TETRAHYDRO-1H-CARBAZOLES BAYER SCHERING PHARMA AG (DE) 2008-11-06 US disclosed
WO-2008116671-A1 2,3,4,9-TETRAHYDRO-1H-CARBAZOLES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-10-02 WO disclosed
EP-1975159-A1 2,3,4,9-Tetrahydro-1H-carbazoles Bayer Schering Pharma Aktiengesellschaft (DE) 2008-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275083-A1 2,3,4,9-TETRAHYDRO-1H-CARBAZOLES FSHR, GNRHR, CYP19A1 HTR2A 953/4885HTR2C 465/4885NR2E1 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.